A study compared the effectiveness of biosimilar anti-TNF drugs to originator drugs for treating juvenile idiopathic arthritis (JIA) using data from the UK JIA Biologics Register. Results showed that at 1 year, 76% of patients who switched to biosimilars and 87% who stayed on originators were still on their drug. The likelihood of stopping the drug was similar for both groups. Changes in disease activity, as measured by JADAS-71 scores, were not significantly different between the two groups. Overall, the study suggests that non-medical switching from originator to biosimilar drugs for JIA is well tolerated and effective.
Source link
Juvenile Idiopathic Arthritis: Biosimilar Data ‘Reassuring’
